Cantor Fitzgerald Expects Reduced Earnings for Zai Lab

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) – Analysts at Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for shares of Zai Lab in a research note issued to investors on Monday, June 23rd. Cantor Fitzgerald analyst L. Watsek now expects that the company will post earnings per share of ($0.94) for the year, down from their prior forecast of ($0.82). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Zai Lab’s current full-year earnings is ($2.58) per share. Cantor Fitzgerald also issued estimates for Zai Lab’s FY2026 earnings at $0.27 EPS.

Zai Lab (NASDAQ:ZLAB) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.05. The company had revenue of $106.49 million for the quarter, compared to analyst estimates of $118.40 million. Zai Lab had a negative return on equity of 33.35% and a negative net margin of 60.26%.

Other equities research analysts have also issued research reports about the company. Scotiabank assumed coverage on Zai Lab in a research report on Friday, March 7th. They set a “sector outperform” rating and a $55.00 target price on the stock. Bank of America reissued a “neutral” rating and set a $36.10 target price (up previously from $29.00) on shares of Zai Lab in a research report on Monday, March 3rd. Finally, JPMorgan Chase & Co. raised their target price on Zai Lab from $44.00 to $51.00 and gave the stock an “overweight” rating in a research report on Thursday, March 13th.

Zai Lab Price Performance

ZLAB stock opened at $36.96 on Wednesday. The firm has a market capitalization of $4.08 billion, a P/E ratio of -14.84 and a beta of 0.96. The business’s 50-day moving average is $33.20 and its two-hundred day moving average is $30.97. Zai Lab has a 1 year low of $16.01 and a 1 year high of $44.34.

Insiders Place Their Bets

In other news, Director William Lis sold 13,814 shares of the stock in a transaction dated Friday, June 20th. The stock was sold at an average price of $35.67, for a total value of $492,745.38. Following the completion of the sale, the director now owns 35,106 shares in the company, valued at approximately $1,252,231.02. This trade represents a 28.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Ying Du sold 46,389 shares of the stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $28.09, for a total value of $1,303,067.01. Following the transaction, the chief executive officer now directly owns 479,851 shares in the company, valued at approximately $13,479,014.59. This represents a 8.82% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 141,021 shares of company stock valued at $4,257,755 over the last quarter. Company insiders own 4.96% of the company’s stock.

Institutional Investors Weigh In On Zai Lab

Several large investors have recently modified their holdings of ZLAB. GF Fund Management CO. LTD. bought a new stake in shares of Zai Lab during the 4th quarter worth $29,000. Pictet Asset Management Holding SA bought a new stake in shares of Zai Lab during the 4th quarter worth $31,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Zai Lab during the 1st quarter worth $75,000. Barclays PLC boosted its stake in shares of Zai Lab by 337.6% during the 4th quarter. Barclays PLC now owns 3,702 shares of the company’s stock worth $97,000 after acquiring an additional 2,856 shares in the last quarter. Finally, Advisors Preferred LLC bought a new stake in shares of Zai Lab during the 1st quarter worth $110,000. 41.65% of the stock is owned by institutional investors.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.